Related Experiment Videos
CALLA-positive myeloma: an aggressive subtype with poor survival
Blood
|July 1, 1985
Summary
Common acute lymphoblastic leukemia antigen (CALLA)-positive myeloma indicates aggressive disease. CALLA positivity in myeloma patients correlates with significantly shorter survival times.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Multiple myeloma is a cancer of plasma cells.
- Immunophenotyping is crucial for classifying myeloma subtypes.
- Understanding myeloma cell surface markers aids in prognosis.
Observation:
- Immunotyping was performed on 21 myeloma bone marrow aspirates and 8 cell lines.
- Four treatment-naive patients and 6 cell lines expressed CALLA.
- CALLA expression was associated with an immature B cell phenotype.
Findings:
- CALLA positivity in myeloma is linked to aggressive disease.
- Median survival for CALLA-positive patients was 6 months.
- CALLA-negative patients had a median survival of 56 months.
Implications:
- CALLA may serve as a prognostic biomarker in multiple myeloma.
- Targeting CALLA could be a therapeutic strategy for aggressive myeloma.
- Further research into CALLA's role in myeloma pathogenesis is warranted.